Anteris Technologies (ASX:AVR) - Aandelenkoers, Nieuws & Analyse

AVR Overzicht aandelen

Anteris Technologies Ltd, een structureel hartbedrijf, houdt zich bezig met het ontwerpen, ontwikkelen en commercialiseren van medische hulpmiddelen.

Over het bedrijf

AVR fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 24.1% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen zinvolle omzet ( A$4M )

Anteris Technologies Ltd Concurrenten

EBR Systems

ASX:EBR

AU$383.9m

Cyclopharm

ASX:CYC

AU$167.3m

Respiri

ASX:RSH

AU$104.6m

Optiscan Imaging

ASX:OIL

AU$137.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Anteris Technologies
Historische aandelenkoersen
Huidige aandelenkoers	AU$10.75
52 Week Hoogtepunt	AU$23.93
52 Week Laag	AU$9.30
Bèta	0.71
11 maand verandering	-11.81%
3 maanden verandering	-28.33%
1 Jaar Verandering	-46.25%
33 jaar verandering	25.00%
5 jaar verandering	62.88%
Verandering sinds IPO	-85.86%

Recent nieuws en updates

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

May 22

Recent updates

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

May 22

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Jul 08

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

May 07

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Feb 21

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

Dec 10

Rendement voor aandeelhouders

	AVR	AU Medical Equipment	AU Markt
7D	-8.5%	-1.4%	-0.5%
1Y	-46.3%	17.1%	19.4%

Rendement versus industrie: AVR presteerde slechter dan de Australian Medical Equipment -sector, die het afgelopen jaar een rendement van 17.1 % opleverde.

Rendement versus markt: AVR presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 19.4 % opleverde.

Prijsvolatiliteit

Is AVR's price volatile compared to industry and market?
AVR volatility
AVR Average Weekly Movement	8.8%
Medical Equipment Industry Average Movement	10.0%
Market Average Movement	8.7%
10% most volatile stocks in AU Market	17.8%
10% least volatile stocks in AU Market	3.6%

Stabiele aandelenkoers: AVR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van AVR is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	n/a	Wayne Paterson	anteristech.com

Anteris Technologies Ltd, een structureel hartbedrijf, houdt zich bezig met het ontwerpen, ontwikkelen en commercialiseren van medische hulpmiddelen. De belangrijkste productkandidaat van het bedrijf is DurAVR, een transkatheter hartklep (THV) voor de behandeling van aortastenose. Het bedrijf biedt ook ComASUR, een toedieningssysteem dat zorgt voor gecontroleerde plaatsing van de DurAVR THV met ballon-expandeerbare toediening, die een precieze uitlijning van de eigen commissuren van het hart mogelijk maakt om de ideale kleppositionering te bereiken; en ADAPT, een gepatenteerde antikalkweefseltechnologie.

Anteris Technologies Ltd Samenvatting

Hoe verhouden de winst en inkomsten van Anteris Technologies zich tot de beurswaarde?
AVR fundamentele statistieken
Marktkapitalisatie	AU$229.58m
Inkomsten(TTM)	-AU$87.90m
Inkomsten(TTM)	AU$3.89m

58.5x

P/S-verhouding

-2.6x

Koers/Winstverhouding

Is AVR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AVR resultatenrekening (TTM)
Inkomsten	AU$3.89m
Kosten van inkomsten	AU$2.25m
Brutowinst	AU$1.63m
Overige uitgaven	AU$89.53m
Inkomsten	-AU$87.90m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-4.16
Brutomarge	42.02%
Nettowinstmarge	-2,260.86%
Schuld/Eigen Vermogen Verhouding	5.3%

Hoe presteerde AVR op de lange termijn?

Bekijk historische prestaties en vergelijking

AVR Overzicht aandelen

Beloningen

Risicoanalyse

Anteris Technologies Ltd Concurrenten

ASX:EBR

AU$383.9m

ASX:CYC

AU$167.3m

ASX:RSH

AU$104.6m

ASX:OIL

AU$137.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus revenue estimates increase by 12%, EPS downgraded

Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity

First half 2024 earnings released: AU$2.75 loss per share (vs AU$2.01 loss in 1H 2023)

Anteris Technologies Ltd has filed a Follow-on Equity Offering in the amount of AUD 30 million.

Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

Recent updates

Consensus revenue estimates increase by 12%, EPS downgraded

Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity

First half 2024 earnings released: AU$2.75 loss per share (vs AU$2.01 loss in 1H 2023)

Anteris Technologies Ltd has filed a Follow-on Equity Offering in the amount of AUD 30 million.

Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021)

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million.

Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP

Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study

Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow

Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston

First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021)

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study

Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients

Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study

Anteris Technologies Ltd Announces Expansion of First in Human Trial

Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million.

Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd, Annual General Meeting, May 19, 2022

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial

Anteris Technologies Ltd Reports New Patent Application for ADAPT

Independent Chairman of the Board exercised options to buy AU$58k worth of stock.

First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020)

Anteris Technologies Ltd announced that it has received AUD 9 million in funding

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million.

Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

New 90-day high: AU$5.52

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Full year 2020 earnings released

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million.

New 90-day high: AU$4.30

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million.

Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

New 90-day low: AU$3.50

Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study

Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes

First half earnings released

New 90-day low - AU$4.30